Engineered T-Cells take aim at Hard-to-Treat pancreatic cancer
NCT ID NCT04809766
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This early-phase trial tests a personalized cell therapy for people with metastatic pancreatic cancer. A patient's own T-cells are genetically modified to recognize and attack mesothelin, a protein found on many pancreatic cancer cells. Before receiving the modified cells, patients get chemotherapy to help the T-cells work better. The study aims to find a safe dose and understand side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mesothelin-specific TCR-T cells (FH-TCR-Tᵐˢˡⁿ)
What this could lead to
If successful, this approach could offer a new treatment option for people with metastatic pancreatic cancer, a disease with very few effective therapies.
What could go wrong
This is an early phase 1 trial with only 9 participants, so safety and dosing are still being evaluated. The therapy may cause serious side effects, and it is too soon to know if it will shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Pancreatic Cancer Trial: Proglumide + Chemo (NCT05827055)
- JAB-23E73 Combo for Pancreatic Cancer Trial NCT07640295
- Peptide Nanovaccine for Advanced Pancreatic Canc NCT07637786
- TCR-T Therapy for Pancreatic Cancer Trial NCT07145450
- Tech-Enhanced Symptom Management for Chemo Patie NCT05038254
- AB801 Trial for Bile Duct & Pancreatic Cancer NCT07619313
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States